CURELAB ONCOLOGY INC.

Dr. Alexander Shneider, CEO
+1-609-841-1201
ashneider@curelab.com
curelaboncology.com

COMPANY BACKGROUND

CureLab Oncology is an immuno-oncology company headquartered in Boston and operating internationally. Our patented product, Elenagen™, acts through two complementary mechanisms. It elicits an immune response against the protein p62/SQSTM1, which is selectively overexpressed in cancer cells. More importantly, it changes the tumor microenvironment, thereby enhancing the anti-cancer potency of other treatments. We aim for it to be used as an adjuvant to **multiple anti-cancer therapies**, viewing others as potential partners, not competitors. By collaborating with leading US and international cancer centers, we are currently in Phase II clinical trials.

Other key attributes:

- Experienced management team
- World-class scientific advisory board
- Leading principal investigator heads up US clinical trials
- Comprehensive IP protection, with patents issued in more than 20 countries

PRODUCT STATUS

- Preclinical proof of concept in a broad spectrum of rodent cancer models and in spontaneous tumors in dogs **>COMPLETED**
- IP protection in all major jurisdictions **> COMPLETED**
- CMC (chemical, manufacturing, and control) **> COMPLETED**
- Pre-clinical toxicology/safety **> COMPLETED**
- Phase I/IIa clinical trials ex-US **> COMPLETED**
- **Proof of clinical benefits in Phase IIb ex-US >COMPLETED/ONGOING**
- Phase IIb in the USA; positive response from FDA to pre-IND appl; **>TRIALS 2023-2025**

DOSE ESCALATION PHASE I/II STUDY: NO TOXICITY; FIRST INDICATIONS OF CLINICAL BENEFITS

Breast & ovarian cancers selected as focus for **Phase II clinical trials in the US/EU**

Primary tumor and metastases disappeared after Elenagen™ + chemo treatment; remained in chemo only.



Restraining ovarian cancer (Phase II Ex-USA)

Platinum-resistant ovarian cancer is a deadly disease with no effective treatment

- Chemotherapy alone: typical disease progression
- **Elenagen + chemotherapy:**
  - **increases progression-free survival time more than 2.5x**
  - **disease did not progress at all in almost 40% of the patients**

Winning the war against breast cancer (Phase II, Ex USA)

- Triple-negative breast cancer (3NBC) is one of the deadliest forms of breast cancer
- Chemotherapy alone: all 3NBC patients suffered disease progression.
- **Elenagen + chemotherapy**: all 3NBC patients demonstrated a complete or partial response:
  - Remote metastasis (lung, liver, bones) disappeared
  - Primary tumors shrank over 50%



PARTNERSHIP WITH GYNECOLOGIC ONCOLOGY GROUP (GOG)

- GOG foundation is the #1 expert community in the USA and highly regarded by the FDA
- Based on our clinical data, GOG has selected CureLab as a strategic partner
  - GOG will provide Advisory Board
  - GOG will develop our clinical strategy
  - GOG will oversee our FDA communication
  - GOG will assist with US clinical centers and supervise our clinical trial

FUNDING

Previous funding:

- *September 2022; $3M cash funding from a prominent biotech investor*
- Previous cash funding ex-US $6M
- Current in-kind funding $3M

Current round: raise $25M

- Obtain FDA 2 IND approvals for clinical trials in the US
- Complete Phase IIb overseas
- Raise a full (final) round of investment
  ⇒ Subtotal: $3M
- Finish 2 Phase II exploratory studies in the US
- License the product out to a big pharma
  ⇒ Subtotal: $19M

Cash reserve $3M

- CRO is investing $3M, providing its entire Phase II work US (FDA) work as an in-kind investment

EXIT STRATEGY

Plan A: license to big pharma; 36 months, target price >$1B

Plan B: public market; 12-18 months

MARKET SIZE

Breast cancer drugs:
2018 – $19B 2026 – $40.5B

Ovarian cancer drugs
2018 – $1.3B 2020 – $2B

UNTAPPED TUMOR MARKET OPPORTUNITY

	Market Size (2026-2028) in Millions
Triple-negative breast cancer	$820
Platinum-resistant ovarian cancer	$6,700
Total solid tumor market	$424,600

PRE-IND COMMUNICATION WITH THE FDA

- Clinical protocol for the Phase II clinical trial was submitted to the FDA
- The FDA cited no major concerns, merely requesting a minor amount of additional data (e.g., repeat a pharmacokinetics experiment including both rat genders)
- Per the FDA request, cumulative toxicity and clinical benefits will be the endpoints of the Phase II clinical trial
- The FDA offered to reduce both the number of patients (60 per disease: 30 Elenagen + 30 control) and the duration of patient observation (presumably, 6 months), saving time and cost.